Cargando…
In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
BACKGROUND: The hematologic response to hydroxyurea (HU) is varied among β-thalassemia (BT) patients. The BCL11A and SOX6 genes are involved in response to HU. This study aimed to investigate the in-vitro responsiveness of HU among BT major patients homozygote for IVSII-1G>A mutation and XmnI sin...
Autores principales: | MAHDAVI, Mohammad Reza, POURFARZAD, Farzin, KOSARYAN, Mehrnoush, AKBARI, Mohammad Taghi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563877/ https://www.ncbi.nlm.nih.gov/pubmed/28845406 |
Ejemplares similares
-
Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia
por: Lebensburger, Jeffrey D, et al.
Publicado: (2015) -
Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System
por: KOSARYAN, Mehrnoush, et al.
Publicado: (2019) -
Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients
por: Bordbar, Mohammad Reza, et al.
Publicado: (2014) -
Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major
por: Khezri, Hadi Darvishi, et al.
Publicado: (2016) -
Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea
por: Zekavat, Omid Reza, et al.
Publicado: (2014)